1,5-Anhydroglucitol in diabetes mellitus

Endocrine

Volumn 43, Issue 1, 2013, Pages 33-40

  Kim, Won Jun ^a   Park, Cheol Young ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

1,5 Anhydroglucitol; Diabetes complication; Diabetes mellitus; Glycemic control; HbA1c

Indexed keywords

1,5 ANHYDROSORBITOL; BIOLOGICAL MARKER; GLUCOSE; HEMOGLOBIN A1C; PROTEIN SGLT4; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ALBUMINURIA; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC INDEX; HUMAN; HYPERGLYCEMIA; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84872280030     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9760-6     Document Type: Review

References (59)

1. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993)
2. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998)
3. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 33, S62-S69 (2011)
4. K.M. Dungan, 1,5-Anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev. Mol. Diagn. 8, 9-19 (2008)
5. T. Yamanouchi, Y. Akanuma, Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res. Clin. Pract. 24(Suppl), S261-S268 (1994)
6. M. Koga, S. Kasayama, Clinical usefulness of glycated albumin as an another glycemic control marker. Endocr. J. 57, 751-762 (2010)
7. T. Yamanouchi, Y. Tachibana, H. Akanuma, S. Minoda, T. Shinohara, H. Moromizato, H. Miyashita, I. Akaoka, Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am. J. Physiol. 263, E268-E273 (1992)
8. T. Yamanouchi, Y. Akanuma, Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res. Clin. Pract. 24, S261-S268 (1994)
9. M. Kishimoto, Y. Yamasaki, M. Kubota, K. Arai, T. Morishima, R. Kawamori, T. Kamada, 1,5-Anhydro-d-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18, 1156-1159 (1995)
10. J.B. Buse, J.L. Freeman, S.V. Edelman, L. Jovanovic, J.B. McGill, Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 5, 355-363 (2003)
11. M. Dworacka, H. Winiarska, M. Szymanska, S. Kuczynski, K. Szczawinska, B. Wierusz-Wysocka, 1,5-anhydro-D-glucitol: a novel marker of glucose excursions. Int J Clin Pract Suppl 129, 40-44 (2002)
12. K.M. Dungan, J.B. Buse, J. Largay, M.M. Kelly, E.A. Button, S. Kato, S. Wittlin, 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29, 1214-1219 (2006)
13. S.N. Mehta, N. Schwartz, J.R. Wood, B.M. Svoren, L.M. Laffel, Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. Pediatr Diabetes 13, 278-284 (2012)
14. M.J. Kim, H.S. Jung, Y. Hwang-Bo, S.W. Cho, H.C. Jang, S.Y. Kim, K.S. Park, Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol. (2011). doi: 10.1007/s00592-011-0302-0
15. M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Habitual intake of dairy products influences serum 1,5-anhydroglucitol levels independently of plasma glucose. Diabetes Res. Clin. Pract. 90, 122-125 (2010)
16. J.K. Kirk, L.V. Passmore, R.A. Bell, K.M. Narayan, R.B. D'Agostino Jr, T.A. Arcury, S.A. Quandt, Disparities in A1C levels between Hispanics and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 31, 240-246 (2008)
17. A.F. Brown, E.W. Gregg, M.R. Stevens, A.J. Karter, M. Weinberger, M.M. Safford, T.L. Gary, D.A. Caputo, B. Waitzfelder, C. Kim, G.L. Beckles, Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the Translating Research into Action for Diabetes (TRIAD) Study. Diabetes Care 28, 2864-2870 (2005)
18. W.H. Herman, K.M. Dungan, B.H. Wolffenbuttel, J.B. Buse, J.L. Fahrbach, H. Jiang, S. Martin, Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 1689-1694 (2009)
19. A.S. Januszewski, C. Karschimkus, K.E. Davis, D. O'Neal, G. Ward, A.J. Jenkins, Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Res. Clin. Pract. 95, e17-e19 (2012)
20. M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Y. Moriwaki, T. Yamamoto, Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system. Clin. Chim. Acta 410, 70-73 (2009)
21. M. Koga, J. Murai, H. Saito, M. Mukai, D. Toya, N. Tanaka, H. Kanehara, Y. Bando, S. Kasayama, 1,5-Anhydroglucitol levels are low irrespective of plasma glucose levels in patients with chronic liver disease. Ann. Clin. Biochem. 48, 121-125 (2011)
22. J. Murai, M. Koga, H. Saito, M. Mukai, S. Kasayama, Serum 1,5-anhydroglucitol is low in gastrectomized men. Acta Diabetol. (2011). doi: 10.1007/s00592-011-0354-1
23. K.E. Kinnaird, T.J. Sauerwein, Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis. Endocr Pract 16, 167-170 (2010)
24. T. Yamanouchi, T. Shinohara, N. Ogata, Y. Tachibana, I. Akaoka, H. Miyashita, Common reabsorption system of 1,5-anhydro-d-glucitol, fructose, and mannose in rat renal tubule. Biochim. Biophys. Acta 1291, 89-95 (1996)
25. S. Tazawa, T. Yamato, H. Fujikura, M. Hiratochi, F. Itoh, M. Tomae, Y. Takemura, H. Maruyama, T. Sugiyama, A. Wakamatsu, T. Isogai, M. Isaji, SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-d-glucitol, and fructose. Life Sci. 76, 1039-1050 (2005)
26. H.S. Freitas, G.F. Anhe, K.F. Melo, M.M. Okamoto, M. Oliveira-Souza, S. Bordin, U.F. Machado, Na-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1 expression and activity. Endocrinology 149, 717-724 (2008)
27. H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, J. Brown, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin dependent diabetes. Diabetes 54, 3427-3434 (2005)
28. N. Nakamura, S. Masuda, K. Takahashi, H. Saito, M. Okuda, K. Inui, Decreased expression of glucose and peptide transporters in rat remnant kidney. Drug Metab. Pharmacokinet. 19, 41-47 (2004)
29. H. Shimizu, A. Shouzu, M. Nishikawa, S. Omoto, T. Hayakawa, Y. Miyake, T. Yonemoto, M. Inada, Serum concentration and renal handling of 1,5-anhydro-d-glucitol in patients with chronic renal failure. Ann. Clin. Biochem. 36, 749-754 (1999)
30. T. Niwa, L. Dewald, J. Sone, T. Miyazaki, M. Kajita, Quantification of serum 1,5-anhydroglucitol in uremic and diabetic patients by liquid chromatography/mass spectrometry. Clin. Chem. 40, 260-264 (1994)
31. H. Yamada, A. Hishida, A. Kato, T. Yoneyama, 1,5-Anhydroglucitol as a marker for the differential diagnosis of acute and chronic renal failure. Nephron 73, 707-709 (1996)
32. W.J. Kim, C.Y. Park, K.B. Lee, S.E. Park, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Park, Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care 35, 281-286 (2012)
33. J.B. McGill, T.G. Cole, W. Nowatzke, S. Houghton, E.B. Ammirati, T. Gautille, M.J. Sarno, 1,5-Anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27, 1859-1865 (2004)
34. K.M. Dungan, J.B. Buse, W.H. Herman, R.F. Arakaki, H.H. Jiang, J.G. Jacobson, J.L. Fahrbach, Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. Diabetes Res. Clin. Pract. 96, e66-e69 (2012)
35. L. Liu, X. Wan, J. Liu, Z. Huang, X. Cao, Y. Li, Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technol. Ther. (2012). doi: 10.1089/dia.2012.0055
36. I. Kawasaki, T. Sato, M. Hosoi, K. Yoshioka, T. Yamakita, M. Fukumoto, N. Tanaka, H. Natsuyama, M. Ueda, S. Fujii, Serum 1,5-anhydroglucitol is a strong predictor of the postprandial hyperglycemia in Type 2 diabetes patients (Abstract). Diabetes 54, A76 (2005)
37. J.C. Won, C.Y. Park, H.S. Park, J.H. Kim, E.S. Choi, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Kim, S.W. Park, 1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Res. Clin. Pract. 84, 51-57 (2009)
38. M. Dworacka, H. Winiarska, The application of plasma 1,5-anhydro-d- glucitol for monitoring type 2 diabetic patients. Dis. Markers 21, 127-132 (2005)
39. J. Sun, J.T. Dou, X.L. Wang, G.Q. Yang, Z.H. Lü, H. Zheng, F.L. Ma, J.M. Lu, Y.M. Mu, Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin. Med. J. (Engl) 124, 3641-3645 (2011)
40. Y. Wang, Y.L. Zhang, Y.P. Wang, C.H. Lei, Z.L. Sun, A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycemic excursions as measured by continuous glucose monitoring system among type 2 diabetes in a Chinese population. Diabetes Metab. Res. Rev. 28, 357-362 (2012)
41. M. Kishimoto, M. Noda, A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc. Diabetol. 22, 115 (2011)
42. T. Yamanouchi, Y. Akanuma, T. Toyota, T. Kuzuya, T. Kawai, S. Kawazu, S. Yoshioka, Y. Kanazawa, M. Ohta, S. Baba, K. Kosaka, Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes 40, 52-57 (1991)
43. S. Tsukui, I. Kobayashi, Effects of age and obesity on glycated haemoglobin and 1,5-anhydroglucitol in screening for type 2 diabetes mellitus. Diabet. Med. 12, 899-903 (1995)
44. M. Goto, R. Yamamoto-Honda, T. Shimbo, A. Goto, Y. Terauchi, Y. Kanazawa, M. Noda, Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. Endocr. J. 58, 13-17 (2011)
45. D.A. Robertson, K.G. Alberti, G.K. Dowse, P. Zimmet, J. Tuomilehto, H. Gareeboo, Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? The Mauritius Noncommunicable Diseases Study Group. Diabet. Med. 10, 56-60 (1993)
46. T.M. Nguyen, L.M. Rodriguez, K.J. Mason, R.A. Heptulla, Serum 1,5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. Pediatr Diabetes 8, 214-219 (2007)
47. A.C. Moses, P. Raskin, N. Khutoryansky, Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. Diabet. Med. 25, 200-205 (2008)
48. R. Beck, M. Steffes, D. Xing, K. Ruedy, N. Mauras, D.M. Wilson, C. Kollman, Diabetes Research in Children Network (DirecNet) Study Group, The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. Pediatr Diabetes 12, 690-695 (2011)
49. M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, A. Imagawa, T. Hanafusa, Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes. Clin. Biochem. 43, 1265-1267 (2010)
50. M. Pontoglio, D. Prié, C. Cheret, A. Doyen, C. Leroy, P. Froguel, G. Velho, M. Yaniv, G. Friedlander, HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 1, 359-365 (2000)
51. A. Pal, A.J. Farmer, C. Dudley, M.P. Selwood, B.A. Barrow, R. Klyne, J.P. Grew, M.I. McCarthy, A.L. Gloyn, K.R. Owen, Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 33, 252-257 (2010)
52. J. Skupien, S. Gorczynska-Kosiorz, T. Klupa, K. Wanic, E.A. Button, J. Sieradzki, M.T. Malecki, Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. Diabetes Care 31, 1496-1501 (2008)
53. W.J. Kim, C.Y. Park, S.E. Park, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Park, S.W. Kim, H.S. Park, Y.J. Kim, S.J. Song, H.Y. Ahn, Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. Diabet. Med. (2012). doi: 10.1111/j.1464-5491.2012.03613.x
54. E. Selvin, L.M. Francis, C.M. Ballantyne, R.C. Hoogeveen, J. Coresh, F.L. Brancati, M.W. Steffes, Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 34, 960-967 (2011)
55. R.A. Kowluru, Q. Zhong, M. Kanwar, Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp. Eye Res. 90, 617-623 (2010)
56. W. Li, X. Liu, M. Yanoff, S. Cohen, X. Ye, Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia 39, 537-547 (1996)
57. M. Dworacka, H. Winiarska, M. Borowska, M. Abramczyk, T. Bobkiewicz-Kozlowska, G. Dworacki, Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. Circ. J. 71, 962-967 (2007)
58. M. Ohira, K. Endo, T. Oyama, T. Yamaguchi, N. Ban, H. Kawana, D. Nagayama, A. Nagumo, A. Saiki, T. Murano, H. Watanabe, Y. Miyashita, K. Shirai, Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 60, 78-85 (2011)
59. M. Watanabe, Y. Kokubo, A. Higashiyama, Y. Ono, Y. Miyamoto, T. Okamura, Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 216, 477-483 (2011)